MAP Infection-Associated Crohn’s Disease: RedHill Biopharma Shows Drug Potential

MAP Infection-Associated Crohn’s Disease: RedHill Biopharma Shows Drug Potential
RedHill Biopharma announced the publication of a peer-review article demonstrating the potential efficacy of RHB-104 for the treatment of Mycobacterium avium subspecies paratuberculosis (MAP) infection-associated Crohn’s disease. The article was authored by researchers from the Burnett School of Biomedical Sciences at the University of Central Florida (UCF) College of Medicine and titled “RHB-104 triple antibiotics combination in culture

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. CJ says:

    Another press release concerning the preconceived notion that CD is definitely caused by MAP- a contentious hypothesis at best. RHB’s most recent publication may demonstrate efficacy of killing MAP in a test tube, but whether stuffing Crohn’s sufferers full of abx for years on end will help them by curtailing hypothetical MAP infection or by simply clearcutting their gastrointestial microbiota remains to be seen. In all likelihood, RHB has no plans to demonstrate efficacy on MAP, but instead simply say “See! It had to have been MAP!” because they stuffed patients full of antibiotics.

Leave a Comment

Your email address will not be published. Required fields are marked *